Robert N. Fried Acquires 10,000 Shares of Chromadex Corp (NASDAQ:CDXC) Stock

Chromadex Corp (NASDAQ:CDXC) CEO Robert N. Fried acquired 10,000 shares of the company’s stock in a transaction dated Thursday, November 14th. The stock was acquired at an average cost of $3.20 per share, with a total value of $32,000.00.

Shares of NASDAQ CDXC traded up $0.10 during mid-day trading on Friday, reaching $3.18. The company’s stock had a trading volume of 391,500 shares, compared to its average volume of 217,203. The firm has a market capitalization of $168.57 million, a PE ratio of -5.20 and a beta of 1.35. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.55 and a quick ratio of 1.11. The stock has a fifty day moving average of $3.31 and a two-hundred day moving average of $4.05. Chromadex Corp has a 52 week low of $2.68 and a 52 week high of $4.95.

Chromadex (NASDAQ:CDXC) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12). The firm had revenue of $12.05 million during the quarter, compared to analyst estimates of $11.66 million. Chromadex had a negative return on equity of 147.85% and a negative net margin of 74.55%. Analysts anticipate that Chromadex Corp will post -0.51 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the stock. Northern Trust Corp boosted its stake in Chromadex by 0.7% during the second quarter. Northern Trust Corp now owns 416,911 shares of the company’s stock valued at $1,939,000 after buying an additional 3,090 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Chromadex by 8.1% during the second quarter. Charles Schwab Investment Management Inc. now owns 91,370 shares of the company’s stock valued at $425,000 after buying an additional 6,880 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Chromadex by 377.2% during the second quarter. JPMorgan Chase & Co. now owns 44,807 shares of the company’s stock valued at $208,000 after buying an additional 35,418 shares during the last quarter. Tieton Capital Management LLC boosted its stake in Chromadex by 5.1% during the second quarter. Tieton Capital Management LLC now owns 1,322,570 shares of the company’s stock valued at $6,150,000 after buying an additional 64,680 shares during the last quarter. Finally, BlackRock Inc. boosted its stake in Chromadex by 15.4% during the second quarter. BlackRock Inc. now owns 2,238,654 shares of the company’s stock valued at $10,410,000 after buying an additional 298,126 shares during the last quarter. 18.29% of the stock is owned by institutional investors.

CDXC has been the subject of a number of recent analyst reports. Zacks Investment Research raised Chromadex from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. Oppenheimer initiated coverage on Chromadex in a research note on Tuesday, October 15th. They issued an “outperform” rating and a $6.00 price objective for the company. Finally, ValuEngine lowered Chromadex from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $6.00.

About Chromadex

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.

See Also: Growth Stocks, What They Are, What They Are Not

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit